Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Breast 3Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 27Ovarian Neoplasms 6Neoplasm Metastasis 5Endometrial Neoplasms 5Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Neoplasms 3Small Cell Lung Carcinoma 2Neoplasms by Site 2Melanoma 2Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Advanced Breast Cancer 2Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Recurrence 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1HR+/HER2- Breast Cancer 1Genetic Diseases, Inborn 1Fallopian Tube Neoplasms 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Colonic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 28enzalutamide 23Specimen Handling 20apalutamide 17Androgen Antagonists 14Radiosurgery 13Radiotherapy 12Prednisone 12Docetaxel 12Abiraterone Acetate 12abiraterone 10Biopsy 10Radiation 8niraparib 6luprolide acetate gel depot 6darolutamide 6Pluvicto 6Leuprolide 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6relugolix 5gallium 68 PSMA-11 5cabazitaxel 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Nivolumab 5Gonadotropin-Releasing Hormone 5bicalutamide 4Triptorelin Pamoate 4Surveys and Questionnaires 4Radiotherapy, Intensity-Modulated 4Glutamate Carboxypeptidase II 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Fulvestrant × 30 days × Clear all
NCT07288359 2026-05-27

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Novartis

Phase 1/2 Recruiting
205 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT06257264 2026-05-11

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BeOne Medicines

Phase 1 Recruiting
258 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07570966 2026-05-06

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Novartis

Phase 1/2 Not yet recruiting
217 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡